Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID L OLIVER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1164404455
CMS profile
623992
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$282.42

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $282.42 6

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $98.06 3
IRONWOOD PHARMACEUTICALS, INC $97.87 1
Esperion Therapeutics, Inc. $71.44 1
Smith+Nephew, Inc. $15.05 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID L OLIVER

NPI 1164404455 · CMS profile ID 623992

Allopathic & Osteopathic Physicians / Family Medicine

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $282.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $71.4410/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737230045 CMS
Lilly USA, LLC $76.6103/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728385367 CMS
Lilly USA, LLC $5.3603/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728394699 CMS
Lilly USA, LLC $16.0903/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728405821 CMS
Smith+Nephew, Inc. $15.0502/07/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 750123143 CMS
IRONWOOD PHARMACEUTICALS, INC $97.8702/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749780691 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $405.23 5
PY2020 $282.42 6
PY2021 $509.12 6
PY2022 $770.26 8
PY2023 $290.27 6
PY2024 $2,305.91 23
PY2025 $352.28 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,288,478.03 35
PY2024 Recipient $48,730.50 2
PY2024 Principal investigator $760,191.54 106
PY2023 Recipient $795.01 2
PY2023 Principal investigator $798,688.88 48
PY2022 Recipient $274.00 1
PY2022 Principal investigator $738,187.49 166
PY2021 Principal investigator $437,882.52 38
PY2020 Recipient $193,202.48 6
PY2020 Principal investigator $298,634.23 42
PY2019 Principal investigator $211,648.73 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Radius Health, Inc. $15.36 12/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778039
Principal investigator 1 Radius Health, Inc. $62.70 12/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778047
Principal investigator 1 Radius Health, Inc. $3,469.00 12/26/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778037
Principal investigator 1 PFIZER INC. $3,200.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665351
Principal investigator 1 PFIZER INC. $250.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665353
Principal investigator 1 PFIZER INC. $1,500.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665437
Principal investigator 1 PFIZER INC. $996.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665527
Principal investigator 1 PFIZER INC. $676.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671667249
Principal investigator 1 PFIZER INC. $6,400.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671667339
Principal investigator 1 PFIZER INC. $3,200.00 12/19/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671667341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,293.58 12/18/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737593
Principal investigator 1 PFIZER INC. $1,250.00 12/16/2019 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671667251
Principal investigator 1 Radius Health, Inc. $1,500.00 11/07/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778013
Principal investigator 1 Radius Health, Inc. $500.00 11/07/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778019
Principal investigator 1 Radius Health, Inc. $4,750.00 11/07/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778027
Principal investigator 1 Radius Health, Inc. $625.00 11/07/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778033
Principal investigator 1 Radius Health, Inc. $500.00 11/07/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778103
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,422.00 11/06/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629163491
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 11/06/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629165621
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 11/06/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629165915
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $407.00 11/06/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629166207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,128.62 10/30/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,895.16 10/30/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737591
Principal investigator 1 Radius Health, Inc. $49.28 10/22/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681778008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $619.40 10/09/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $937.04 10/09/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62,632.40 10/09/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,671.12 09/18/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737581
Principal investigator 1 Radius Health, Inc. $0.20 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777565
Principal investigator 1 Radius Health, Inc. $0.40 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777571
Principal investigator 1 Radius Health, Inc. $1.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777575
Principal investigator 1 Radius Health, Inc. $1.42 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777581
Principal investigator 1 Radius Health, Inc. $125.70 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777587
Principal investigator 1 Radius Health, Inc. $13.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777595
Principal investigator 1 Radius Health, Inc. $137.40 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777599
Principal investigator 1 Radius Health, Inc. $141.80 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777606
Principal investigator 1 Radius Health, Inc. $2.80 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777611
Principal investigator 1 Radius Health, Inc. $23.37 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777615
Principal investigator 1 Radius Health, Inc. $38.20 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777621
Principal investigator 1 Radius Health, Inc. $39.15 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777627
Principal investigator 1 Radius Health, Inc. $400.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777633
Principal investigator 1 Radius Health, Inc. $500.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777639
Principal investigator 1 Radius Health, Inc. $57.30 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777643
Principal investigator 1 Radius Health, Inc. $93.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777648
Principal investigator 1 Radius Health, Inc. $0.02 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777651
Principal investigator 1 Radius Health, Inc. $0.04 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777657
Principal investigator 1 Radius Health, Inc. $45.00 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777663
Principal investigator 1 Radius Health, Inc. $65.45 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777669
Principal investigator 1 Radius Health, Inc. $0.20 08/30/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 681777961
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,422.00 07/10/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629163181
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 07/10/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629164415
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,422.00 07/10/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629165021
Principal investigator 1 PFIZER INC. $800.00 07/05/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665349
Principal investigator 1 PFIZER INC. $250.00 07/05/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665433
Principal investigator 1 PFIZER INC. $3,850.00 07/05/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671665435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $920.00 07/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737579
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $155.42 06/19/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629165323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,750.00 05/29/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,125.00 05/29/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 05/29/2019 Non-covered Recipient Entity
RENSTAR INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639737577
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,088.00 05/08/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629166491
Principal investigator 1 PFIZER INC. $7,689.40 05/02/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671654743
Principal investigator 1 PFIZER INC. $6,147.60 05/02/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671654745
Principal investigator 1 PFIZER INC. $6,147.60 05/02/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655153
Principal investigator 1 PFIZER INC. $7,689.40 05/02/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655157
Principal investigator 1 PFIZER INC. $2,137.20 05/02/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655377
Principal investigator 1 PFIZER INC. $7,689.40 04/03/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655193
Principal investigator 1 PFIZER INC. $7,074.60 04/03/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655195
Principal investigator 1 PFIZER INC. $3,200.00 03/18/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671655133
Principal investigator 1 PFIZER INC. $2,259.40 03/12/2019 Non-covered Recipient Entity
Renstar LLC
A PHASE 3 MULTICENTER LONGTERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE HIP OR SHOULDER REPLACEMENT No dispute reported 06/30/2026 671655179
Principal investigator 1 PFIZER INC. $48.00 03/01/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671654227
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $519.20 02/21/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629163801
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $519.20 02/21/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629164109
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $519.20 02/21/2019 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629164719
Principal investigator 1 PFIZER INC. $48.00 02/01/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671654285
Principal investigator 1 PFIZER INC. $48.00 01/01/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671654339